Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02396511 · ClinicalTrials.gov registry record · Phase 2
TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma
A Phase 2 study of Choriocarcinoma, sponsored by Tracon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT02396511 is a Phase 2 study of Choriocarcinoma that has completed, run by Tracon Pharmaceuticals. The registered enrollment target is 2 participants, below the 368-participant average among 5 other Choriocarcinoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02396511, a Phase 2 study of Choriocarcinoma, has completed, sponsored by Tracon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine whether TRC105 in combination with Bevacizumab is effective in the treatment of two patients with metastatic and refractory choriocarcinoma.
Conditions Studied
Interventions
- BIOLOGICAL Bevacizumab
- BIOLOGICAL TRC105
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Insititue - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-01 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02396511
The ClinicalTrials.gov registry entry for NCT02396511 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 368-participant average among 5 other Choriocarcinoma trials with a reported enrollment target (99% lower). The listed sponsor is Tracon Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Choriocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02396511 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02396511 about?
NCT02396511 is a clinical study titled "TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma". The purpose of this study is to determine whether TRC105 in combination with Bevacizumab is effective in the treatment of two patients with metastatic and refractory choriocarcinoma.
What is the current status of trial NCT02396511?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2015-01. Estimated completion is 2017-12.
What conditions does trial NCT02396511 study?
This clinical trial studies the following conditions: Choriocarcinoma.
What interventions are being tested in trial NCT02396511?
The interventions under investigation include: Bevacizumab (BIOLOGICAL), TRC105 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02396511?
This trial is sponsored by Tracon Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02396511 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choriocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
RECRUITING · Phase 2
-
A Trial for Patients With Gestational Trophoblastic Disease
COMPLETED · Phase 2
-
Molecular Epidemiology of Pediatric Germ Cell Tumors
RECRUITING
-
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
ACTIVE NOT RECRUITING · Phase 3
-
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.